ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.
Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence. ICON also provides strategic consulting and commercialization support, helping clients address operational, scientific and regulatory requirements across the product life cycle.
Founded in Dublin, Ireland, in 1990, ICON has expanded into a global organization serving clients across North America, Europe, Asia-Pacific and other international markets. The company became a publicly traded company on Nasdaq in 1998 and significantly expanded its capabilities through the acquisition of PRA Health Sciences in 2021.
ICON is led by Chief Executive Officer Steve Cutler, who has held the role since 2017. Its broad international operations and range of outsourced development services position the company as a partner for organizations conducting clinical research and developing innovative healthcare products.
AI Generated. May Contain Errors.
